| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e77f06144be4708a6ae75bd9fee56a4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S530-806
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16722 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-01 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| filingDate |
1989-07-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee7b70dcbdeec1424368826d890337c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0bed02d886bf792a074a925a5fefcd2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abc6ee4e977887b8aaab8b75bbd13028
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_48b67c73c1f3c14ac7c817792f275160
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d67a69c141a2a0f2c745ff0c4a1362f |
| publicationDate |
1990-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0353809-A1 |
| titleOfInvention |
Pseudorabies virus vaccine |
| abstract |
The present invention is concerned with a pseudorabies virus (PRV) vaccine comprising a polypeptide of the PRV glycoprotein gII or a fragment thereof which was shown to be the site of interaction of PRV neutralizing antibodies. Vector vaccines capable to express a polynucleotide fragment coding for such a polypeptide also form part of the present invention. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105814077-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021123104-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105814077-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0927760-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6960442-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7122653-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2667245-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0479627-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0927760-A2 |
| priorityDate |
1988-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |